Posted by Michael Wonder on 24 May 2022
HLS Therapeutics obtains public reimbursement for Vascepa in Quebec
24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular disease.
HLS Therapeutics announces that it has successfully entered into a product listing agreement with the Quebec Minister of Health and Social Services, for the listing and public reimbursement of Vascepa (icosapent ethyl) on the Public Prescription Drug Insurance Plan of the Régime de l'Assurance Maladie du Québec, effective 26 May 2022.
